69 related articles for article (PubMed ID: 11316044)
1. Dengue virus specific T cell responses to live attenuated monovalent dengue-2 and tetravalent dengue vaccines.
Rabablert J; Dharakul T; Yoksan S; Bhamarapravati N
Asian Pac J Allergy Immunol; 2000 Dec; 18(4):227-35. PubMed ID: 11316044
[TBL] [Abstract][Full Text] [Related]
2. Differential dengue cross-reactive and neutralizing antibody responses in BALB/c and Swiss albino mice induced by immunization with flaviviral vaccines and by infection with homotypic dengue-2 virus strains.
Lim CS; Chua JJ; Wilkerson J; Chow VT
Viral Immunol; 2006; 19(1):33-41. PubMed ID: 16553548
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults.
Kitchener S; Nissen M; Nasveld P; Forrat R; Yoksan S; Lang J; Saluzzo JF
Vaccine; 2006 Feb; 24(9):1238-41. PubMed ID: 16213632
[TBL] [Abstract][Full Text] [Related]
4. Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen.
Apt D; Raviprakash K; Brinkman A; Semyonov A; Yang S; Skinner C; Diehl L; Lyons R; Porter K; Punnonen J
Vaccine; 2006 Jan; 24(3):335-44. PubMed ID: 16125280
[TBL] [Abstract][Full Text] [Related]
5. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine.
Guy B; Chanthavanich P; Gimenez S; Sirivichayakul C; Sabchareon A; Begue S; Yoksan S; Luxemburger C; Lang J
Vaccine; 2004 Sep; 22(27-28):3563-74. PubMed ID: 15315835
[TBL] [Abstract][Full Text] [Related]
6. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys.
Blaney JE; Matro JM; Murphy BR; Whitehead SS
J Virol; 2005 May; 79(9):5516-28. PubMed ID: 15827166
[TBL] [Abstract][Full Text] [Related]
7. Dengue virus-specific memory T cell responses in human volunteers receiving a live attenuated dengue virus type 2 candidate vaccine.
Dharakul T; Kurane I; Bhamarapravati N; Yoksan S; Vaughn DW; Hoke CH; Ennis FA
J Infect Dis; 1994 Jul; 170(1):27-33. PubMed ID: 7912253
[TBL] [Abstract][Full Text] [Related]
8. Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine.
Rothman AL; Kanesa-thasan N; West K; Janus J; Saluzzo JF; Ennis FA
Vaccine; 2001 Sep; 19(32):4694-9. PubMed ID: 11535318
[TBL] [Abstract][Full Text] [Related]
9. Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice.
Konishi E; Kosugi S; Imoto J
Vaccine; 2006 Mar; 24(12):2200-7. PubMed ID: 16316713
[TBL] [Abstract][Full Text] [Related]
10. Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination.
Sun W; Nisalak A; Gettayacamin M; Eckels KH; Putnak JR; Vaughn DW; Innis BL; Thomas SJ; Endy TP
J Infect Dis; 2006 Jun; 193(12):1658-65. PubMed ID: 16703509
[TBL] [Abstract][Full Text] [Related]
11. Serological response of foals to polyvalent and monovalent live-attenuated African horse sickness virus vaccines.
Crafford JE; Lourens CW; Smit TK; Gardner IA; MacLachlan NJ; Guthrie AJ
Vaccine; 2014 Jun; 32(29):3611-6. PubMed ID: 24814557
[TBL] [Abstract][Full Text] [Related]
12. Chimeric dengue type 2/type 1 viruses induce immune responses in cynomolgus monkeys.
Butrapet S; Rabablert J; Angsubhakorn S; Wiriyarat W; Huang C; Kinney R; Punyim S; Bhamarapravati N
Southeast Asian J Trop Med Public Health; 2002 Sep; 33(3):589-99. PubMed ID: 12693596
[TBL] [Abstract][Full Text] [Related]
13. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of sanofi pasteur tetravalent dengue vaccine.
Guy B
J Clin Virol; 2009 Oct; 46 Suppl 2():S16-9. PubMed ID: 19800561
[TBL] [Abstract][Full Text] [Related]
15. Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development.
Thomas SJ; Hombach J; Barrett A
Vaccine; 2009 Jan; 27(3):355-68. PubMed ID: 19022321
[TBL] [Abstract][Full Text] [Related]
16. An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes.
Khanam S; Rajendra P; Khanna N; Swaminathan S
BMC Biotechnol; 2007 Feb; 7():10. PubMed ID: 17302980
[TBL] [Abstract][Full Text] [Related]
17. The role of pre-existing cross-reactive antibodies in determining the efficacy of vaccination in humans: study protocol for a randomized controlled trial.
Low JG; Wijaya L; Li GK; Lim EY; Shum AK; Cheung YB; Ooi EE
Trials; 2015 Apr; 16():147. PubMed ID: 25872531
[TBL] [Abstract][Full Text] [Related]
18. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
[TBL] [Abstract][Full Text] [Related]
19. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects.
Guy B; Nougarede N; Begue S; Sanchez V; Souag N; Carre M; Chambonneau L; Morrisson DN; Shaw D; Qiao M; Dumas R; Lang J; Forrat R
Vaccine; 2008 Oct; 26(45):5712-21. PubMed ID: 18762226
[TBL] [Abstract][Full Text] [Related]
20. Serotype-specific T(H)1 responses in recipients of two doses of candidate live-attenuated dengue virus vaccines.
Gwinn W; Sun W; Innis BL; Caudill J; King AD
Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):39-47. PubMed ID: 14740954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
